Loading...
XSHG600529
Market cap2.20bUSD
Jan 09, Last price  
24.26CNY
1D
-0.61%
1Q
-9.85%
Jan 2017
123.59%
Name

Shandong Pharmaceutical Glass Co.

Chart & Performance

D1W1MN
XSHG:600529 chart
P/E
20.75
P/S
3.23
EPS
1.17
Div Yield, %
1.24%
Shrs. gr., 5y
2.12%
Rev. gr., 5y
14.03%
Revenues
4.98b
+18.98%
560,177,649672,138,979826,714,2321,012,129,7571,158,292,0671,242,158,5221,513,418,3071,397,177,9951,468,092,8311,544,544,9521,691,112,4561,723,207,1652,057,473,0592,330,488,3512,584,627,1612,992,346,7513,427,069,4723,875,304,6634,187,279,2794,982,198,167
Net income
776m
+25.48%
75,658,06682,484,07694,055,248111,013,512141,991,489144,361,875171,330,127132,532,983119,828,142122,333,707124,702,667145,407,381189,604,926262,758,070358,209,968458,687,262564,439,557591,088,499618,287,086775,802,014
CFO
1.05b
+315.14%
044,086,95378,468,091122,632,73591,758,958249,269,436217,011,545274,626,29128,519,302268,597,934266,634,293389,634,256506,528,107411,962,940465,773,178599,051,285566,009,160750,440,353252,442,3241,047,982,969
Dividend
Oct 11, 20240.3 CNY/sh
Earnings
May 16, 2025

Profile

Shandong Pharmaceutical Glass Co., Ltd manufactures and sells pharmaceutical glass packaging and butyl rubber series products in China. It offers pharma glass packaging products, such as molded injection glass vials, food-grade bottles, clear cosmetic bottles, cobalt blue and green bottles, tubular glass vials, ampoules, glass tubing products, amber glass bottles, and other borosilicate glass products; butyl rubber stoppers; prefilled syringes, plastic and aluminum caps, plastic caps, and plastic bottles; and dropper caps and Teflon coated rubber stoppers. The company sells its products to the pharmaceutical, food, and cosmetic glass packaging industries. It also exports its products to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and other countries. Shandong Pharmaceutical Glass Co., Ltd was founded in 1970 and is based in Zibo, China.
URL
http://www.pharmglass.com/
IPO date
Jun 03, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,982,198
18.98%
4,187,279
8.05%
Cost of revenue
3,876,420
3,338,115
Unusual Expense (Income)
NOPBT
1,105,778
849,164
NOPBT Margin
22.19%
20.28%
Operating Taxes
135,022
89,764
Tax Rate
12.21%
10.57%
NOPAT
970,756
759,401
Net income
775,802
25.48%
618,287
4.60%
Dividends
(199,084)
(178,490)
Dividend yield
1.17%
1.05%
Proceeds from repurchase of equity
1,842,470
BB yield
-10.81%
Debt
Debt current
1,826
5,202
Long-term debt
Deferred revenue
57,621
58,946
Other long-term liabilities
(7,313)
Net debt
(2,682,458)
(2,448,282)
Cash flow
Cash from operating activities
1,047,983
252,442
CAPEX
(671,530)
Cash from investing activities
(744,567)
Cash from financing activities
(186,619)
1,668,180
FCF
265,905
563,585
Balance
Cash
2,684,233
2,453,484
Long term investments
50
Excess cash
2,435,173
2,244,120
Stockholders' equity
4,888,702
4,315,873
Invested Capital
5,158,782
4,727,434
ROIC
19.64%
16.64%
ROCE
14.56%
12.17%
EV
Common stock shares outstanding
663,079
600,279
Price
25.60
-9.86%
28.40
-35.31%
Market cap
16,974,813
-0.43%
17,047,916
-34.73%
EV
14,292,356
14,599,634
EBITDA
1,430,906
1,144,338
EV/EBITDA
9.99
12.76
Interest
3,057
Interest/NOPBT
0.28%